We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DiaMedica Therapeutics Inc | NASDAQ:DMAC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.42% | 2.39 | 2.40 | 2.51 | 2.42 | 2.25 | 2.41 | 21,248 | 22:14:27 |
From Jun 2023 to Jun 2024
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13th. DiaMedica will host a live conference call on Tuesday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results.
Conference Call details:
Date:
Tuesday, November 14, 2023
Time:
7:00 AM CT / 8:00 AM ET
Web access:
https://app.webinar.net/OVpdLmgYMDE
Dial In:
(877) 550-1858
Conference ID:
1754341
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 21, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231106951994/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941 ppapi@diamedica.com
1 Year DiaMedica Therapeutics Chart |
1 Month DiaMedica Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
